Cargando…

Incidence and risk factors for pneumonitis among patients with lung cancer who received immune checkpoint inhibitors after palliative thoracic radiotherapy

The aim of this study is to analyze the incidence and risk factors for pneumonitis when immune checkpoint inhibitors (ICIs) are combined with palliative thoracic radiotherapy (RT) for lung cancer. We retrospectively evaluated 29 patients with lung cancer who received ICIs after palliative thoracic R...

Descripción completa

Detalles Bibliográficos
Autores principales:	Saito, Satoshi, Abe, Takanori, Iino, Misaki, Aoshika, Tomomi, Ryuno, Yasuhiro, Ohta, Tomohiro, Igari, Mitsunobu, Hirai, Ryuta, Kumazaki, Yu, Yamaguchi, Ou, Kaira, Kyoichi, Kagamu, Hiroshi, Noda, Shin-ei, Kato, Shingo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Oncology/Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8273801/ https://www.ncbi.nlm.nih.gov/pubmed/34121123 http://dx.doi.org/10.1093/jrr/rrab051

Ejemplares similares

Feasibility of intensity modulated radiotherapy with involved field radiotherapy for Japanese patients with locally advanced non-small cell lung cancer
por: Abe, Takanori, et al.
Publicado: (2021)

Effect of durvalumab on local control after concurrent chemoradiotherapy for locally advanced non‐small cell lung cancer in comparison with chemoradiotherapy alone
por: Abe, Takanori, et al.
Publicado: (2020)

Simple method for evaluating achievement degree of lung dose optimization in individual patients with locally advanced non‐small cell lung cancer treated with intensity modulated radiotherapy
por: Abe, Takanori, et al.
Publicado: (2022)

Incidence and dose-volume relationship of radiation pneumonitis after concurrent chemoradiotherapy followed by durvalumab for locally advanced non-small cell lung cancer
por: Saito, Satoshi, et al.
Publicado: (2020)

High-dose stereotactic body radiotherapy using CyberKnife® for stage I peripheral lung cancer: a single-center retrospective study
por: Ryuno, Yasuhiro, et al.
Publicado: (2022)

Learning curve of lung dose optimization in intensity‐modulated radiotherapy for locally advanced non‐small cell lung cancer
por: Igari, Mitsunobu, et al.
Publicado: (2023)

Stereotactic body radiation therapy using CyberKnife for T1N0M0 lung cancer patients with severe pulmonary dysfunction
por: Abe, Takanori, et al.
Publicado: (2020)

Results of definitive radiotherapy with concurrent chemotherapy for maxillary sinus carcinomas with neck lymph node metastasis
por: Abe, Takanori, et al.
Publicado: (2020)

Development of an HDR‐BT QA tool for source position verification
por: Kumazaki, Yu, et al.
Publicado: (2020)

Dose–volume parameters and local tumor control in cervical cancer treated with central-shielding external-beam radiotherapy and CT-based image-guided brachytherapy
por: Okazaki, Shohei, et al.
Publicado: (2019)

Dosimetric comparison of three-dimensional conformal radiotherapy versus volumetric-arc radiotherapy in cervical cancer treatment: applying the central-shielding principle to modern technology
por: Tamaki, Tomoaki, et al.
Publicado: (2018)

Chemoradiotherapy followed by durvalumab in patients with unresectable advanced non‐small cell lung cancer: Management of adverse events
por: Miura, Yu, et al.
Publicado: (2020)

Value of (18)F-FDG-PET to predict PD-L1 expression and outcomes of PD-1 inhibition therapy in human cancers
por: Kaira, Kyoichi, et al.
Publicado: (2021)

Perspective of Immune Checkpoint Inhibitors in Thymic Carcinoma
por: Kaira, Kyoichi, et al.
Publicado: (2021)

Advanced Research on Immune Checkpoint Inhibitor Therapy
por: Imai, Hisao, et al.
Publicado: (2022)

Radiotherapy is an independent prognostic marker of favorable prognosis in non‐small cell lung cancer patients after treatment with the immune checkpoint inhibitor, nivolumab
por: Yamaguchi, Ou, et al.
Publicado: (2019)

A phase II study of daily carboplatin plus irradiation followed by durvalumab for stage III non-small cell lung cancer patients with PS 2 up to 74 years old and patients with PS 0 or 1 from 75 years: NEJ039A (trial in progress)
por: Kaira, Kyoichi, et al.
Publicado: (2020)

Primary thymic adenocarcinoma with an aggressive clinical course: An autopsy case showing signet ring cell‐like features
por: Shiono, Ayako, et al.
Publicado: (2020)

Spontaneous aspiration of a long tree twig as foreign body
por: Hashimoto, Kosuke, et al.
Publicado: (2019)

Osimertinib induced cardiomyopathy: A case report
por: Shinomiya, Shun, et al.
Publicado: (2020)

Salvage Chemotherapy in Patients with Previously Treated Thymic Carcinoma
por: Kaira, Kyoichi, et al.
Publicado: (2021)

Clinical Effectiveness of Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer with a Poor Performance Status
por: Kaira, Kyoichi, et al.
Publicado: (2021)

Clinical significance of primary prophylactic pegylated‐granulocyte‐colony stimulating factor after the administration of ramucirumab plus docetaxel in patients with previously treated non‐small cell lung cancer
por: Mouri, Atsuto, et al.
Publicado: (2019)

Transbronchial Cryobiopsy for Miliary Tuberculosis Mimicking Hypersensitivity Pneumonitis
por: Nasu, Shingo, et al.
Publicado: (2020)

Combination of immune check inhibitor and immunomodulatory arabinomannan extracted from Mycobacterium tuberculosis: A case report
por: Kobayashi, Kunihiko, et al.
Publicado: (2021)

Dilemma Concerning the Differential Diagnosis of Hematological Malignancy and Bone Metastasis Arising from Lung Cancer
por: Kaira, Kyoichi
Publicado: (2022)

Assessing cumulative dose distributions in combined radiotherapy for cervical cancer using deformable image registration with pre-imaging preparations
por: Abe, Takanori, et al.
Publicado: (2014)

Tumor metabolic volume by (18)F-FDG-PET as a prognostic predictor of first-line pembrolizumab for NSCLC patients with PD-L1 ≥ 50%
por: Yamaguchi, Ou, et al.
Publicado: (2020)

Potential of FDG-PET as Prognostic Significance after anti-PD-1 Antibody against Patients with Previously Treated Non-Small Cell Lung Cancer
por: Hashimoto, Kosuke, et al.
Publicado: (2020)

Effectiveness of EGFR‐TKI rechallenge immediately after PD‐1 blockade failure
por: Kaira, Kyoichi, et al.
Publicado: (2021)

Effect of Systemic Steroid Use for Immune-Related Adverse Events in Patients with Non-Small Cell Lung Cancer Receiving PD-1 Blockade Drugs
por: Mouri, Atsuto, et al.
Publicado: (2021)

Intrapericardial carboplatin in the management of malignant pericardial effusion in breast cancer: a pilot study
por: Kotake, Mie, et al.
Publicado: (2019)

Waterproofing spray-associated pneumonitis review: Comparison with acute eosinophilic pneumonia and hypersensitivity pneumonitis
por: Shimoda, Masafumi, et al.
Publicado: (2021)

Hypersensitivity Pneumonitis Caused by Exposure to a Gray Parrot (Psittacus erithacus)
por: Enomoto, Takanori, et al.
Publicado: (2021)

Different incidence of interstitial lung disease according to different kinds of EGFR‐tyrosine kinase inhibitors administered immediately before and/or after anti‐PD‐1 antibodies in lung cancer
por: Uchida, Takahiro, et al.
Publicado: (2019)

Improved efficacy of ramucirumab plus docetaxel after nivolumab failure in previously treated non‐small cell lung cancer patients
por: Shiono, Ayako, et al.
Publicado: (2019)

Pre‐existing interstitial lung disease does not affect prognosis in non‐small cell lung cancer patients with PD‐L1 expression ≥50% on first‐line pembrolizumab
por: Yamaguchi, Ou, et al.
Publicado: (2020)

Efficacy and Feasibility of Programmed Death-1/Programmed Death Ligand-1 Blockade Therapy in Non-Small Cell Lung Cancer Patients With High Antinuclear Antibody Titers
por: Mouri, Atsuto, et al.
Publicado: (2021)

Pretreatment body mass index predicts survival among patients administered nivolumab monotherapy for pretreated non‐small cell lung cancer
por: Imai, Hisao, et al.
Publicado: (2022)

Prognostic significance of tumor infiltrating lymphocytes on first-line pembrolizumab efficacy in advanced non-small cell lung cancer
por: Kaira, Kyoichi, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_q012t6368cdkqg95r65v8cjnpj